Related Experiment Video
Updated: Aug 2, 2026

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
Published on: March 30, 2014
Establishment of cross-resistance profiles for new agents
Abstract:
Sublines of murine leukemias (L1210 and P388) and solid tumors selected for resistance to representatives of all of the chemical and functional classes of clinically useful anticancer drugs have been isolated and established in serial in vivo passage and, in some cases, in vitro culture. Extensive resistance, cross-resistance, and collateral-sensitivity patterns have been established with most of the sublines of the drug-resistant murine leukemias under treatment with greater than 100 different established and clinically useful anticancer drugs or new candidate anticancer drugs currently under study. Patients selected for inclusion in phase I-II trials usually have tumors that have failed to respond to treatment with established clinically useful drugs, either from the start of treatment or during continuing treatment after initial useful response. These treatment failures are no doubt due, in many cases, to drug-resistant tumors if initially unresponsive or to the overgrowth of drug-resistant mutant tumor stem cells in initially responding patients who ultimately failed under continuing treatment. Therefore, the cross-resistance profiles of drug-resistant murine tumors to treatment with new drugs going into phase I-II trials should provide useful guides for patient selection for those trials. Also, these cross-resistance profiles will provide useful information indicating likely biochemical mechanism of action of new drugs with promising anticancer activity, thus guiding drug selection for combination chemotherapy trials in animals or man. Numerous examples of all of the above indications for useful application of such information derived from chemotherapy trials with drug-resistant murine tumors are reported.
Insights
Developing drug-resistant cancer models in mice helps predict patient treatment outcomes. Understanding cross-resistance patterns guides the selection of effective anticancer drugs for clinical trials and combination therapies.
Area of Science:
- Oncology
- Pharmacology
- Translational Research
Background:
- Acquired resistance to anticancer drugs is a major challenge in cancer therapy.
- Drug-resistant tumor sublines are crucial for preclinical studies.
- Understanding resistance mechanisms informs clinical trial design and patient selection.
Purpose of the Study:
- To establish and characterize drug-resistant murine leukemia and solid tumor sublines.
- To investigate cross-resistance and collateral sensitivity patterns against a broad spectrum of anticancer drugs.
- To evaluate the utility of these models in predicting clinical outcomes and guiding new drug development.
Main Methods:
- Selection of L1210 and P388 murine leukemia sublines for resistance to diverse anticancer agents.
- Serial in vivo passage and in vitro culture of resistant tumor sublines.
- Comprehensive drug sensitivity and cross-resistance profiling using over 100 anticancer drugs.
Main Results:
- Established multiple drug-resistant sublines of murine leukemias and solid tumors.
- Characterized extensive resistance, cross-resistance, and collateral sensitivity profiles.
- Demonstrated the predictive value of murine models for clinical drug response.
Conclusions:
- Drug-resistant murine tumor models provide valuable insights into clinical drug resistance.
- Cross-resistance profiles aid in patient selection for clinical trials.
- These models facilitate the identification of mechanisms of action and guide combination chemotherapy strategies.
More Related Videos
08:46Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
Related Concept Videos
Treatment Resistant Cancers
Factors Affecting Drug Response: Overview
Clinically Relevant Drug Product Specifications: Methods of Establishment
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase